Fidaxomicin meets Phase III endpoint

Optimer Pharmaceuticals Inc. (NASDAQ:OPTR) said fidaxomicin ( OPT-80) was non-inferior to Vancocin vancomycin on

Read the full 145 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE